<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543465</url>
  </required_header>
  <id_info>
    <org_study_id>0782-003</org_study_id>
    <secondary_id>2007_636</secondary_id>
    <nct_id>NCT00543465</nct_id>
  </id_info>
  <brief_title>12-Week No-Rofecoxib Plus Aspirin Endoscopy Study (0782-003)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study will look at the incidence of gastric and/or duodenal ulcers in patients with
      osteoarthritis or rheumatoid arthritis in four different treatment groups (a) MK0782 21 mg
      plus enteric-coated aspirin, (b) MK0782 42 mg plus enteric-coated aspirin, (c) celecoxib 200
      mg plus enteric-coated aspirin, and enteric-coated aspiring alone.

      This is an early phase trial and some specific protocol information is in progress and not
      publicly available at this time. (Full information is available to trial participants).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <enrollment type="Actual">49</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <condition>Osteoarthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0782</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has osteoarthritis or rheumatoid arthritis for at least 6 months prior to start of
             study

          -  Osteoarthritis (OA): must have diagnosis of OA in knee, hip, hand or spine

        Patient is not on chronic aspirin therapy (taking aspirin at any dose, on a daily basis,
        for a minimum of 4 weeks prior to Visit 2 for any medical condition

          -  Must be willing to limit alcohol use to no more than 2 drinks per day

          -  Avoid strenuous physical activity

        Exclusion Criteria:

          -  Mentally or legally incapacitated

          -  Has systemic lupus erythematosus, Paget's disease

          -  Has a history of esophageal, gastric biliary, or small intestine surgery (hiatal
             surgeries and any GI surgery that causes clinical malabsorption or delayed gastric
             emptying

          -  Has uncontrolled hypertension

          -  Has uncontrolled diabetes

          -  Has had heart attack, unstable angina, coronary angioplasty, stent placement, coronary
             artery bypass grafting in the last 6 months

          -  Has congestive heart failure

          -  Has had active liver disease within the last 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2007</study_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

